IL322666A - תכשיר הכולל אנטיגן hbv לטיפול בהפטיטיס b - Google Patents
תכשיר הכולל אנטיגן hbv לטיפול בהפטיטיס bInfo
- Publication number
- IL322666A IL322666A IL322666A IL32266625A IL322666A IL 322666 A IL322666 A IL 322666A IL 322666 A IL322666 A IL 322666A IL 32266625 A IL32266625 A IL 32266625A IL 322666 A IL322666 A IL 322666A
- Authority
- IL
- Israel
- Prior art keywords
- hbv
- hbsag
- dose
- hbcag
- vaccination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23162520 | 2023-03-17 | ||
| PCT/EP2024/053631 WO2024193905A1 (en) | 2023-03-17 | 2024-02-13 | Hbv antigen formulation for treating hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322666A true IL322666A (he) | 2025-10-01 |
Family
ID=85704064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322666A IL322666A (he) | 2023-03-17 | 2024-02-13 | תכשיר הכולל אנטיגן hbv לטיפול בהפטיטיס b |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4680277A1 (he) |
| CN (1) | CN121443308A (he) |
| AU (1) | AU2024241503A1 (he) |
| IL (1) | IL322666A (he) |
| WO (1) | WO2024193905A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025172435A1 (en) * | 2024-02-13 | 2025-08-21 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Hbv antigen formulation for treating hepatitis b |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| EP1845164B1 (en) | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
| EP2042604A1 (en) | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| KR102873711B1 (ko) * | 2016-01-12 | 2025-10-21 | 울리케 프로처 | Hbv를 치료하기 위한 수단 및 방법 |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
-
2024
- 2024-02-13 EP EP24709658.9A patent/EP4680277A1/en active Pending
- 2024-02-13 WO PCT/EP2024/053631 patent/WO2024193905A1/en not_active Ceased
- 2024-02-13 CN CN202480033241.8A patent/CN121443308A/zh active Pending
- 2024-02-13 AU AU2024241503A patent/AU2024241503A1/en active Pending
- 2024-02-13 IL IL322666A patent/IL322666A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121443308A (zh) | 2026-01-30 |
| AU2024241503A1 (en) | 2025-08-14 |
| WO2024193905A1 (en) | 2024-09-26 |
| EP4680277A1 (en) | 2026-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7636804B2 (ja) | Ｂ型肝炎ウイルスコアタンパク質および表面抗原タンパク質をコードする核酸分子ならびにそれを含むワクチン | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| IL295548A (he) | הרכבים אימונוגניים של נגיף הקורונה ושימושים בהם | |
| TWI623618B (zh) | Ｈｂｖ聚合酶突變體 | |
| US11684668B2 (en) | Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence | |
| TWI555531B (zh) | 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物 | |
| IL297795A (he) | חיסוני sars-cov-2 | |
| Zhang et al. | A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice | |
| US12403190B2 (en) | Coronavirus vaccine and methods of use thereof | |
| IL271461B2 (he) | חלקיקים כימריים דמויי-ווירוס ושימושים בהם כמנתבי מטרה ספציפיים-לאנטיגן של תגובה אימונית | |
| Natami et al. | RETRACTED ARTICLE: An overview on mRNA-based vaccines to prevent monkeypox infection | |
| JP2025508676A (ja) | オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法 | |
| IL322666A (he) | תכשיר הכולל אנטיגן hbv לטיפול בהפטיטיס b | |
| US20110129489A1 (en) | Methods for generating an immune response using dna and a viral vector | |
| CN111836640A (zh) | 乙型肝炎免疫方案和组合物 | |
| CN118076646A (zh) | 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用 | |
| Huang et al. | Prophylactic and therapeutic HBV vaccination by an HBs‐expressing cytomegalovirus vector lacking an interferon antagonist in mice | |
| JP2024520730A (ja) | コロナウイルスに対するウイルス様粒子ワクチン | |
| IL292433A (he) | תרכיב חלקיקים דמויי נגיף צ'יקונגוניה ושיטות לשימוש בו | |
| Hong et al. | Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice | |
| WO2025172435A1 (en) | Hbv antigen formulation for treating hepatitis b | |
| Su et al. | Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| Russell et al. | PreS1-decorated recombinant adenovirus encoding HBV antigens generates neutralizing humoral and cellular immunity | |
| IL322488A (he) | חיסון רב-ציסטרוני ושיטות לייצור ושימוש בו |